Cristin-resultat-ID: 1802024
Sist endret: 22. mars 2020, 12:11
NVI-rapporteringsår: 2019
Resultat
Vitenskapelig artikkel
2019

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Bidragsytere:
  • Uma Ramaswamia
  • Marta Futemab
  • Martin Prøven Bogsrud
  • Kirsten Bjørklund Holven
  • Jeanine Roeters van Lennep
  • Albert Wiegmang
  • mfl.

Tidsskrift

Atherosclerosis
ISSN 0021-9150
e-ISSN 1879-1484
NVI-nivå 2

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2019
Publisert online: 2019
Trykket: 2020
Volum: 292
Sider: 178 - 187
Open Access

Importkilder

Scopus-ID: 2-s2.0-85075795827

Beskrivelse Beskrivelse

Tittel

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Sammendrag

Abstract Background and aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European guidelines recommend consideration of statin therapy by age 8–10 years for those with a low density lipoprotein cholesterol (LDL-C)>3.5 mmol/l, and dietary and lifestyle advice. Here we compare the characteristics and lipid levels in HeFH children from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. Methods: Fully-anonymized data were analysed at the London centre. Differences in registration and on treatment characteristics were compared by standard statistical tests. Results: Data was obtained from 3064 children. The median age at diagnosis differed significantly between countries (range 3–11 years) reflecting differences in diagnostic strategies. Mean (SD) LDL-C at diagnosis was 5.70 (±1.4) mmol/l, with 88% having LDL-C>4.0 mmol/l. The proportion of children older than 10 years at follow-up who were receiving statins varied significantly (99% in Greece, 56% in UK), as did the proportion taking Ezetimibe (0% in UK, 78% in Greece). Overall, treatment reduced LDL-C by between 28 and 57%, however, in those>10 years, 23% of on-treatment children still had LDL-C>3.5 mmol/l and 66% of those not on a statin had LDL-C>3.5 mmol/l. Conclusions: The age of HeFH diagnosis in children varies significantly across 8 countries, as does the proportion of those>10 years being treated with statin and/or ezetimibe. Approximately a quarter of the treated children and almost three quarters of the untreated children older than 10 years still have LDL-C concentrations over 3.5 mmol/l. These data suggest that many children with FH are not receiving the full potential benefit of early identification and appropriate lipid-lowering treatment according to recommendations.

Bidragsytere

Uma Ramaswamia

  • Tilknyttet:
    Forfatter
    ved Royal London Hospital

Marta Futemab

  • Tilknyttet:
    Forfatter
    ved University College London

Martin Prøven Bogsrud

  • Tilknyttet:
    Forfatter
    ved Avdeling for medisinsk genetikk ved Oslo universitetssykehus HF
  • Tilknyttet:
    Forfatter
    ved Endokrinologi, sykelig overvekt og foreb. Med., avd. for ved Oslo universitetssykehus HF

Kirsten Bjørklund Holven

  • Tilknyttet:
    Forfatter
    ved Seksjon for klinisk ernæring ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Endokrinologi, sykelig overvekt og foreb. Med., avd. for ved Oslo universitetssykehus HF

Jeanine Roeters van Lennep

  • Tilknyttet:
    Forfatter
    ved Erasmus MC: Universitair Medisch Centrum Rotterdam
1 - 5 av 15 | Neste | Siste »